NxStage Medical (NXTM) : Oracle Investment Management Inc reduced its stake in NxStage Medical by 18.12% during the most recent quarter end. The investment management company now holds a total of 2,694,636 shares of NxStage Medical which is valued at $68,605,433 after selling 596,365 shares in NxStage Medical , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.NxStage Medical makes up approximately 12.55% of Oracle Investment Management Inc’s portfolio.
Other Hedge Funds, Including , Cubist Systematic Strategies reduced its stake in NXTM by selling 5,263 shares or 45.82% in the most recent quarter. The Hedge Fund company now holds 6,223 shares of NXTM which is valued at $158,438. NxStage Medical makes up approx 0.01% of Cubist Systematic Strategies’s portfolio.Johnson Financial Group boosted its stake in NXTM in the latest quarter, The investment management firm added 1,129 additional shares and now holds a total of 1,424 shares of NxStage Medical which is valued at $36,255.Cortina Asset Management reduced its stake in NXTM by selling 317,106 shares or 15.59% in the most recent quarter. The Hedge Fund company now holds 1,717,194 shares of NXTM which is valued at $43,719,759. NxStage Medical makes up approx 1.87% of Cortina Asset Management’s portfolio.Chartwell Investment Partners boosted its stake in NXTM in the latest quarter, The investment management firm added 60,040 additional shares and now holds a total of 315,520 shares of NxStage Medical which is valued at $7,550,394. NxStage Medical makes up approx 0.13% of Chartwell Investment Partners’s portfolio.
NxStage Medical opened for trading at $22.82 and hit $23.06 on the upside on Thursday, eventually ending the session at $22.865, with a gain of 0.02% or 0.005 points. The heightened volatility saw the trading volume jump to 2,16,524 shares. Company has a market cap of $1,476 M.
On the company’s financial health, NxStage Medical reported $-0.03 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.04. The company had revenue of $92.20 million for the quarter, compared to analysts expectations of $89.30 million. The company’s revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.08 EPS.
Many Wall Street Analysts have commented on NxStage Medical. NxStage Medical was Upgraded by Northland Capital to ” Outperform” on Jun 28, 2016.
NxStage Medical Inc. is a medical device company. The Company is engaged in the development manufacturing and marketing of products for the treatment of kidney failure fluid overload and related blood treatments and procedures. The Companys products include the System One Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles. Its primary product the System One is a small portable easy-to-use hemodialysis system. It is designed to deliver the therapeutic flexibility and clinical benefits associated with traditional dialysis machines in a smaller portable easy-to-use form that can be used by healthcare professionals and trained lay users alike in a variety of settings including patient homes as well as more traditional care settings such as hospitals and dialysis centers. The Company operates in three reportable business segments: System One In-Center and Services.